SCHEMBL5726231

SCHEMBL5726231

O=C(c1ccc(OCCOCc2ccccc2)cc1)C(CCOC1CCCCO1)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
SMN1; SMN2 Q16637 9/20 0.42
LMNA P02545 6/20 0.42
MAPT P10636 3/20 0.42
TP53 P04637 2/20 0.42
JAK2 O60674 2/20 0.42
THRB P10828 1/20 0.42
MITF O75030 3/20 0.41
RAB9A P51151 1/20 0.41
NLRP1 Q9C000 1/20 0.41
PAX8 Q06710 1/20 0.38
FOXM1 Q08050 1/20 0.38
GAA P10253 1/20 0.37
KDM4C Q9H3R0 1/20 0.37
KDM4E B2RXH2 1/20 0.37
CHRM4 P08173 1/20 0.37
ALDH1A1 P00352 2/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5725306 0.99 KMT2A (0.52) KMT2AMEN1SMN1; SMN2LMNAMAPT
SCHEMBL5726245 0.94 KMT2A (0.49) KMT2AMEN1SMN1; SMN2LMNAMAPT
SCHEMBL5725637 0.84 MEN1 (0.50) KMT2AMEN1SMN1; SMN2LMNAMAPT
SCHEMBL9860590 0.84 SMN1; SMN2 (0.52) KMT2AMEN1SMN1; SMN2LMNAMAPT
SCHEMBL5725870 0.80 TBXAS1 (0.49) KMT2AMEN1SMN1; SMN2LMNA
SCHEMBL9860310 0.80 MEN1 (0.53) KMT2AMEN1SMN1; SMN2LMNAMAPT
SCHEMBL9860360 0.79 MEN1 (0.54) KMT2AMEN1SMN1; SMN2LMNAMAPT
SCHEMBL25278062 0.77 FOXM1 (0.58) KMT2AMEN1SMN1; SMN2LMNATP53
SCHEMBL27083259 0.77 MEN1 (0.66) KMT2AMEN1SMN1; SMN2LMNAMAPT
SCHEMBL25221323 0.76 KMT2A (0.57) KMT2AMEN1SMN1; SMN2LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1705169-A2 Triphenylalkene derivatives and their use as selective estrogen receptor modulators Hormos Medical Ltd. (FI) 2006-09-27 EP disclosed
EP-1235776-B1 TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS HORMOS MEDICAL CORP (FI) 2006-02-08 EP disclosed
US-6875775-B2 Triphenylalkene derivatives and their use as selective estrogen receptor modulators HORMOS MEDICAL OY LTD (FI) 2005-04-05 US disclosed
US-20030225130-A1 Triphenylalkene derivatives and their use as selective estrogen receptor modulators HORMOS MEDICAL OY LTD. 2003-12-04 US disclosed
US-6576645-B1 Such as 3-(4-chloro-1-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)--2-phenylbut-1 -enyl)phenol; producing tissue specific estro-genic and/or antiestrogenic effect HORMOS MEDICAL OY LTD (FI) 2003-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225130-A1 Triphenylalkene derivatives and their use as selective estrogen receptor modulators ESR2, ESR1, GPER1 KMT2A 987/4885MEN1 3414/4885SMN1; SMN2 4365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.